title: Effect of transforming growth factor-beta 1 on myocardial stunning in the intact dog.
abstract: Previous studies have demonstrated that transforming growth factor-beta (TGF-beta) can accelerate wound healing, inhibit free radical formation and limit myocardial ischemia/reperfusion injury in a variety of experimental models. However, it is unknown whether exogenous TGF-beta 1 can attenuate the prolonged contractile dysfunction that is observed after a brief, reversible ischemic insult (myocardial stunning). Thus, open-chest dogs undergoing a 15-min left anterior descending coronary artery occlusion and 4 h of reperfusion were given TGF-beta 1 as an intravenous bolus (250 micrograms) at 24 h and again at 1 h before coronary occlusion (n = 5). Control dogs (n = 7) received equivalent amounts of vehicle. The two groups were similar with respect to occluded bed size, collateral blood flow and rate-pressure product. Fundamental physiological parameters, such as body temperature, arterial pH, PO2 and hematocrit, were within normal limits throughout the experiment. In control dogs, regional myocardial function (assessed as systolic thickening fraction) remained depressed throughout the 4 h reperfusion period, indicating severe myocardial stunning. TGF-beta 1 did not produce any significant improvement in the recovery of regional function; 4 h after reperfusion, paradoxical systolic thinning was still present in both treated and control groups, with thickening fraction being -22.5 +/- 6.1% and -31.0 +/- 5.3% of baseline, respectively (P = N.S.). These results demonstrate that a large dose of TGF-beta 1 given before ischemia fails to attenuate myocardial stunning in the open-chest dog, suggesting that this growth factor does not exert protective effects in the setting of reversible myocardial ischemia/reperfusion injury.
authors.affiliation: Department of Medicine, Baylor College of Medicine, Houston, Texas 77030.
authors.forename: J Z
authors.initials: JZ
authors.lastname: Sun
authors.forename: X Y
authors.initials: XY
authors.lastname: Li
authors.forename: M B
authors.initials: MB
authors.lastname: Sporn
authors.forename: M D
authors.initials: MD
authors.lastname: Schneider
authors.forename: R
authors.initials: R
authors.lastname: Roberts
authors.forename: R
authors.initials: R
authors.lastname: Bolli
mesh_terms: D000208:Acute Disease; D000818:Animals; D004285:Dogs; D005260:Female; D005609:Free Radicals; D006439:Hemodynamics; D008297:Male; D009200:Myocardial Contraction; D017202:Myocardial Ischemia / Q000188:drug therapy*; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D010084:Oxidation-Reduction; D013778:Tetrazolium Salts; D016212:Transforming Growth Factor beta / Q000627:therapeutic use*
chemical_list: D005609:Free Radicals; D013778:Tetrazolium Salts; D016212:Transforming Growth Factor beta; C009591:triphenyltetrazolium